J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval

2nd August 2017 Uncategorised 0

AbbVie may have shelled out a whole lot of money to gain access to Imbruvica, but the med keeps paying off. On Wednesday, the FDA approved the product for chronic graft-versus-host disease, marking the first time it’s green-lighted any med in that area.

More: J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
Source: fierce